| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 02/05/2008 | US7326708 Phosphoric acid salt of a dipeptidyl peptidase-IV inhibitor |
| 02/05/2008 | US7326707 Bicyclic melanocortin-specific compounds |
| 02/05/2008 | US7326706 Pyrazine modulators of cannabinoid receptors |
| 02/05/2008 | US7326705 2-amino or carbonylamino-4-carbocyclic imidazoles and thiazoles; antiischemic agents, hypotensive agents, antiarrhythmia agents; can be coadministered with other drugs |
| 02/05/2008 | US7326704 Iminobenzoxazines, iminobenzthiazines and iminoquinazolines for controlling invertebrate pests |
| 02/05/2008 | US7326703 (1,10B-Dihydro-2-(aminocarbonyl-phenyl)-5H-pyrazolo[1,5-c][1,3]benzoxazin-5-yl)phenyl methanone derivatives as HIV viral replication inhibitors |
| 02/05/2008 | US7326702 antibiotics, fungicides, viricides; treating microbial infections; fused rings based on 1,4-benzoxazino(2,3,4-ij)quinolin-4-one for example |
| 02/05/2008 | US7326701 Lactam compounds and pharmaceutical use thereof |
| 02/05/2008 | US7326700 Prevention of prelabor during pregnancy; central nervous system disorders, psychological disorders |
| 02/05/2008 | US7326699 4-Amino-5-phenyl-7-cyclobutyl-pyrrolo(2,3-d)pyrimidine derivatives |
| 02/05/2008 | US7326698 Prostaglandin analogs |
| 02/05/2008 | US7326697 Methods for increasing the therapeutic response to electroconvulsive therapy |
| 02/05/2008 | US7326696 Amino-methyl substituted tetracycline compounds |
| 02/05/2008 | US7326695 Anti-bacterial agents based upon oxoanion binding |
| 02/05/2008 | US7326694 Administering a 6-mercaptopurine drug; determining a level of 6-thioguanine; wherein level of 6-mercaptopurine metabolite greater than predetermined toxic level of 6-mercaptopurine metabolite indicates a need to decrease amount |
| 02/05/2008 | US7326693 Antisense modulation of c-reactive protein expression |
| 02/05/2008 | US7326692 Induction of immunity using inhibitors of granzymes |
| 02/05/2008 | US7326691 Pulmonary and/or nasal fungal infection |
| 02/05/2008 | US7326690 Buffer intracellular reduction and oxidation for the stressed cells in various disease states; beneficial as adjunctive support therapy, multiple chemical sensitivity syndrome, Charcot-Marie-Tooth disease, Dejerine-Sottas syndrome, Roussy-Levy syndrome, Rosenberg Chutorian syndrome, Korsakoff syndrome |
| 02/05/2008 | US7326685 Diagnostic or therapeutic somatostatin or bombesin analog conjugates and uses thereof |
| 02/05/2008 | US7326545 Chlamydia antigens and corresponding DNA fragments and uses thereof |
| 02/05/2008 | US7326542 Compositions and methods for regulating bacterial pathogenesis |
| 02/05/2008 | US7326426 Compositions and medical devices utilizing bioabsorbable liquid polymers |
| 02/05/2008 | US7326421 Device and methods for sequential, regional delivery of multiple cytotoxic agents and directed assembly of wound repair tissues |
| 02/05/2008 | US7326420 Adding tert-amine (terbinafine) to peroxide at the time of skin application to increase radicals formed on the body and further increasing efficacy, e.g., heat, light, electrical stimulation, antioxidant, penetrant, transition metal, physically manipulating the skin; killing surface microorganisms |
| 02/05/2008 | US7326418 Identification of novel factors that block programmed cell death or apoptosis by targeting JNK |
| 02/05/2008 | US7326245 Medical device for delivering biologically active material |
| 02/05/2008 | US7325355 Methods for treatment of atherosclerosis using 1,3-dioxo-2-(2,6-dioxopiperidin-3-yl)-4-aminoisoindoline |
| 02/05/2008 | CA2609626A1 Composition comprising l-arginine, crataegus, artichoke flavonoids and citruilline for improving blood flow in working muscles |
| 02/05/2008 | CA2436269C Artificial tear composition containing a combination of three demulcents |
| 02/05/2008 | CA2420847C Process for producing erythromycin derivative |
| 02/05/2008 | CA2417635C Heterocyclic compounds useful as inhibitors of tyrosine kinases |
| 02/05/2008 | CA2413515C Carbamate and thiocarbamate podophyllotoxin derivatives, preparation method and pharmaceutical compositions containing them |
| 02/05/2008 | CA2402686C Vitronectin receptor antagonist bicyclic compounds, preparation method and compositions containing same |
| 02/05/2008 | CA2395204C Piperidinyloxy and pyrrolidinyloxyphenyl oxazolidinones as antibacterials |
| 02/05/2008 | CA2390746C Quinolinone derivative pharmaceutical composition and production method therefor |
| 02/05/2008 | CA2383315C New derivatives of pyrimidin-4-ones, the process for the preparation thereof and the pharmaceutical compounds that contain them |
| 02/05/2008 | CA2349227C Substituted 2-phenylbenzimidazoles, the production thereof and their use |
| 02/05/2008 | CA2339272C Nitrogen-containing heterocyclic carboxamide derivatives or salts thereof and antiviral agents comprising the same |
| 02/05/2008 | CA2315703C Tripeptidyl peptidase inhibitors |
| 02/05/2008 | CA2315685C Molecular dispersion composition with enhanced bioavailability |
| 02/05/2008 | CA2313618C Transmucosal formulations of levosimendan |
| 02/05/2008 | CA2302276C Methods of treating capsules and dry, powdered pharmaceutical formulations |
| 02/05/2008 | CA2293720C Improved method for preparing low-concentration polyaluminosilicate microgels |
| 02/05/2008 | CA2289206C Efficient enantioselective addition reaction using an organozinc reagent |
| 02/05/2008 | CA2284977C 3,3-disubstituted propylamines, their use and preparation |
| 02/05/2008 | CA2281642C Substituted 2,4-diaminopyrimidines |
| 02/05/2008 | CA2278140C Administration of products of the 5-lipoxygenase metabolic pathway to enhance antimicrobial defense |
| 02/05/2008 | CA2274556C Compositions for the systemic control of parasites of warm-blooded animals |
| 02/05/2008 | CA2274485C Medicinal composition |
| 02/05/2008 | CA2264065C Acylaminoalkenylene-amide derivatives as nk1 and nk2 antagonists |
| 02/05/2008 | CA2205406C Novel benzyl pyrimidines |
| 02/05/2008 | CA2199893C 1,25-dihydroxy-16,22,23-trisdehydro-cholecalciferol derivatives |
| 02/05/2008 | CA2191077C Vinca-alkaloid vesicles with enhanced efficacy and tumor targeting properties |
| 02/05/2008 | CA2187161C Dna encoding precursor of interleukin-1.beta. converting enzyme-related cysteine proteinase ii (icerel-ii) |
| 02/05/2008 | CA2179304C Stent for liberating drug |
| 02/05/2008 | CA2166155C Agents binding to hyaluronic acid binding domains and the use thereof |
| 01/31/2008 | WO2008014497A2 Aldh-2 inhibitors in the treatment of addiction |
| 01/31/2008 | WO2008014478A2 Nanocell drug delivery system |
| 01/31/2008 | WO2008014471A1 Drug combination pharmaceutical compositions and methods for using them |
| 01/31/2008 | WO2008014457A1 Monoamine oxidase inhibitors useful for treating disorders of the outer retina |
| 01/31/2008 | WO2008014431A2 Method of treating ocular infections |
| 01/31/2008 | WO2008014430A1 Arylsulfanyl compounds and compositions for delivering active agents |
| 01/31/2008 | WO2008014381A2 Modulators of chemokine receptor activity, crystalline forms and process |
| 01/31/2008 | WO2008014361A2 Cyclic derivatives as modulators of chemokine receptor activity |
| 01/31/2008 | WO2008014360A2 Modulators of chemokine receptor activity, crystalline forms and process |
| 01/31/2008 | WO2008014338A2 Antagonists of endothelial differentiation gene subfamily 3 (edg-3, s1p3) receptors for prevention and treatment of ocular disorders |
| 01/31/2008 | WO2008014311A2 Inhibitors of undecaprenyl pyrophosphate synthase |
| 01/31/2008 | WO2008014307A2 Inhibitors of undecaprenyl pyrophosphate synthase |
| 01/31/2008 | WO2008014299A2 Use of an alpha2-agonist composition for the treatment of hyperlipidemia |
| 01/31/2008 | WO2008014291A2 Compounds and compositions as hedgehog signaling pathway modulators |
| 01/31/2008 | WO2008014286A1 Vinyl phosphonate lysophosphatidic acid receptor antagonists |
| 01/31/2008 | WO2008014266A2 Heme oxygenase inhibitors and methods of therapeutic use |
| 01/31/2008 | WO2008014252A2 Iap inhibitors |
| 01/31/2008 | WO2008014247A2 4 -arylalkoxymethyl-4- phenyl piperidines and their use as neurokinin receptor antagonists for the treatment of cns disorders |
| 01/31/2008 | WO2008014236A1 Dimeric iap inhibitors |
| 01/31/2008 | WO2008014232A2 Pharmaceutical formulations for the treatment of alzheimer's disease |
| 01/31/2008 | WO2008014222A1 Crystalline forms of rapamycin analogs |
| 01/31/2008 | WO2008014221A2 Bridged carbamate macrolides |
| 01/31/2008 | WO2008014219A2 Thiozolidinedione derivatives as p13 kinase inhibitors |
| 01/31/2008 | WO2008014186A1 2-phenyl-indoles as prostaglandin d2 receptor antagonists |
| 01/31/2008 | WO2008014108A2 Antimicrobial oxazolidinone prodrugs |
| 01/31/2008 | WO2008014066A1 Nfkappab inhibitors to treat pain locally |
| 01/31/2008 | WO2008013988A2 Method of treating a condition associated with phosphorylation of task-1 |
| 01/31/2008 | WO2008013986A2 Compositions and methods for treating or preventing ophthalmic light toxicity |
| 01/31/2008 | WO2008013985A2 Use of heat shock activators for tissue regeneration |
| 01/31/2008 | WO2008013984A2 Compositions and methods for treating or preventing ophthalmic disease |
| 01/31/2008 | WO2008013983A2 Opsin stabilizing compounds and methods of use |
| 01/31/2008 | WO2008013966A2 Use of 8-quinolinol and its analogs to target cancer stem cells |
| 01/31/2008 | WO2008013963A2 Fatty acid amide hydrolase inhibitors |
| 01/31/2008 | WO2008013962A2 Method and mixture for in-vivo photochemical cross-linking of collagen |
| 01/31/2008 | WO2008013929A2 Anti-migraine oral spray formulations and methods |
| 01/31/2008 | WO2008013925A2 Fungicidal azocyclic amides |
| 01/31/2008 | WO2008013913A2 Method and device for minimally invasive site specific ocular drug delivery |
| 01/31/2008 | WO2008013899A2 Rhamnolipid-based formulations |
| 01/31/2008 | WO2008013866A2 Methods for treating acute acoustic trauma |
| 01/31/2008 | WO2008013860A2 Acyloxyalkyl carbamate prodrugs of alpha-amino acids, methods of synthesis and use |
| 01/31/2008 | WO2008013840A2 Erastin analogs and uses thereof |
| 01/31/2008 | WO2008013807A2 A novel lactic acid formulation of mk-0457 useful for the treatment of cancer |
| 01/31/2008 | WO2008013799A2 Treatment and prevention of cardiovascular disease using mast cell stabilizers |